Biofilms Treatment Market Overview
The Biofilms Treatment Market Predictable at $18.36 billion in 2022, is estimated to increase at a CAGR of 10.35% from $ 23.37 billion in 2023 to $34.45 billion by 2030.
The word "biofilms" refers to a group of microorganisms that colonise various surfaces. The bacteria, fungus, and protists that produce biofilms are microorganisms. Biofilms can develop on the surface of the earth, in the ground, underground, or on minerals. Animal tissues, plant tissues, and implanted medical equipment like catheters and pacemakers can all contain biofilms.
In other terms, biofilm is referred to be a community of microorganisms that includes cells and extracellular matrix and is prone to adhering to surfaces. Bacteria use biofilm development as a means of survival. Numerous cutting-edge methods are employed in analysing and researching biofilm physiology, including metagenomics, metatranscriptomics, fluorescence, CLSM, and the FISH technique.
The demand for biofilms therapy in the healthcare sector has increased due to an increase in wounds and hospital-acquired illnesses. Treatment of biofilms is necessary to prevent contamination since implanted devices like pacemakers and catheters are the main locations for biofilm formation. According to the survey, biofilms are present inside 60% to 70% of chronic wounds. It is anticipated that this factor will hasten market expansion.
>>>Download Sample Report Now: https://marketreportservice.com/request-sample/biofilms-treatment-market-54425
Important features of debridement tools for treating biofilms include:
Sharp Debridement: The biofilm and wounded tissue are physically removed using surgical implements like scalpels and scissors.
Mechanical Debridement: Biofilm and debris are manually removed during dressing changes using debridement tools such wet-to-dry dressings and specialised pads.
Enzymatic Debridement: During enzymatic debridement, applying topical enzymes to the wound aids in the breakdown of biofilm and dead tissue.
Autolytic Debridement: The natural process of autolytic debridement is facilitated by a wet wound environment, enabling the body's enzymes to disintegrate biofilm and necrotic tissue.
Biofilms Treatment Market Segment Analysis
The market for gauzes and dressings is categorized into various products like debridement tools, gauzes and dressings, grafts, wipes, pads, lavage solutions, gels, ointments, and sprays. The gauzes & dressing sector is expected to have a significant revenue share in the global market. Daily application of surfactant gel dressing and wiping can reduce biofilm to undetectable levels in a skin explant model after three days.
Due to the increasing need for these treatments, the debridement equipment segment is anticipated to experience consistently rapid revenue growth during the projected period. Debridement is a crucial component of wound care in order to prepare the wound bed for re-epithelialization. Bacteria feed on necrotic tissue in particular as well as distorted tissue in general. Additionally, deviated tissue acts as a physical barrier to re-epithelialization, preventing topical drugs from directly penetrating the wound bed and having a therapeutic impact. Necrotic tissue also prevents the production of granulation tissue, regular Extracellular Matrix (ECM), and epidermal resurfacing. Not to mention, the presence of necrotic tissue might obscure potential infections and make it harder for the doctor to assess the size and severity of the wound.
Market Dynamics
Drivers
The biofilms treatment market is expected to grow in the forecast period of 2022-2030 due to factors such as increasing patient population, ageing population, improved treatment options, diabetes and obesity, and enhanced treatment options. Additionally, growing demand from developing countries will create opportunities for treating biofilms, driving the market growth.
The demand for biofilm in healthcare has surged due to the rise in wounds and hospital-acquired illnesses. Biofilm growth is primarily found in implanted devices like catheters and pacemakers, necessitating treatment to prevent contamination. Biofilms are found in 60% to 70% of chronic wounds, indicating a potential market expansion.
Restraints
The biofilms treatment market report highlights the challenges faced by the market, including rising treatment costs, low wound care product penetration, shortage of qualified workers, and lack of healthcare facilities in developing nations. It also discusses recent developments, trade regulations, production analysis, value chain optimization, market share, and the impact of domestic and localized players. Opportunities include new revenue pockets, regulatory changes, strategic market growth, market size, category growths, application niches, product approvals, and geog.
Competitive Landscape of the Biofilms Treatment Market
- Smith+Nephew (U.K.)
- MiMedx (U.S.)
- ConvaTec Group plc (U.K.)
- Coloplast Group (Denmark)
- Mölnlycke Healthcare AB (Sweden)
- Organogenesis Inc. (U.S.)
- Integra LifeSciences (U.S.)
- Braun Melsungen AG (Germany)
- PAUL HARTMANN AG (Germany)
- Medline Industries Inc. (U.K.)
- Acelity (U.S.)
- Misonix (U.S.)
- Zimmer Biomet (U.S.)
- Kerecis (Iceland)
- Welcare Industries S.p.A (Italy)
Recent Developments in Biofilms Treatment Market
On May 4, 2023, Trellis Bioscience revealed positive interim phase 1 findings regarding TRL1068, an innovative native human monoclonal antibody designed to alleviate the impact of bacterial biofilm in chronic prosthetic joint infections. TRL1068 has demonstrated the capability to eradicate bacterial biofilm, thereby enabling the use of conventional antibiotics for the treatment of challenging bacterial infections.
Integra LifeSciences Completes and Surgical Innovation Associates: In 2022, Integra LifeSciences Holdings Corporation, a leading global medical technology company, announced it has successfully completed its acquisition of Surgical Innovation Associates (SIA). This acquisition is a highly strategic move to enable us to achieve our aspirations to become a global leader and innovator of implant-based breast reconstruction (IBBR) procedures.
MIMEDX Announces Wound & Surgical Product Pipeline Expansion: In 2022, MiMedx Group, Inc., a pioneer and leader in placental biologics, announced that it has licensed worldwide exclusive rights to Turn Therapeutics’ proprietary antimicrobial technology platform, PermaFusion®, for the development of future biologic products focused on wound and surgical recovery applications.
Regional Analysis
Why is the US a lucrative market for manufacturers of biofilm treatment products?
North America is embracing advanced wound care solutions, including biofilm-related treatments, to improve patient outcomes. Hospitals and wound care facilities are using advanced dressings and medicines to combat biofilms. Researchers have developed a 3D printing technique that precisely arranges bacteria within hydrogel, a clear, gel-like substance. The process involves mapping bacteria in droplets of liquid hydrogel resin and solidifying the material using laser light to create a crude biofilm. The growing number of collaborations in this region is expected to boost revenue.
China is a crucial market for biofilm treatment providers due to its high demand and high-quality products.
The Asia Pacific region is experiencing a surge in wound care awareness, particularly among the elderly population with diabetes. This trend is driven by increased educational and outreach programs, which encourage early biofilm management detection, prompt interventions, and improved wound healing outcomes. China's growing older population, particularly those with diabetes, is driving market expansion, as diabetes can lead to diabetic foot ulcers that require dressing treatment.
Segments Covered in the Biofilms Treatment Market Report
By Product:
- Debridement Equipment
- Gauzes
- Dressings
- Gels
- Ointments
By Wound Type:
- Traumatic Wounds
- Surgical Wounds
- Open Wounds
- Diabetic Foot Wounds
- Venous Leg Ulcers
- Burns Wounds
By End User:
- Hospitals
- Ambulatory Surgical Centers
- Wound Care Centers
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Frequently Asked Questions
What is the expected growth rate of the Biofilms Treatment market over the next 7 years?
The Biofilms Treatment Market Predictable at $18.36 billion in 2022, is estimated to increase at a CAGR of 10.35% from $ 23.37 billion in 2023 to $34.45 billion by 2030.
Who are the major players in the Biofilms Treatment market and what is their market share?
Smith+Nephew (U.K.), MiMedx (U.S.), ConvaTec Group plc (U.K.), Coloplast Group (Denmark), Mölnlycke Healthcare AB (Sweden), Organogenesis Inc. (U.S.), Integra LifeSciences (U.S.), B. Braun Melsungen AG (Germany), PAUL HARTMANN AG (Germany), Medline Industries Inc. (U.K.), Acelity (U.S.), Misonix (U.S.), Zimmer Biomet (U.S.), Kerecis (Iceland), Welcare Industries S.p.A (Italy), are prominent players operating and dominating in the market.
Which Region is expected to witness the highest growth in the Biofilms Treatment Market?
The Biofilms Treatment market is predicted to experience the most significant growth in the United States region over the next seven years.
What is the anticipated demand in China for the treatment of biofilms?
Through 2030, China's demand for biofilm treatment is anticipated to grow at a CAGR of 10.35%.
1.SUMMARY
1.1. Biofilms Treatment Market Overview
1.2. Key Insights
1.3. Report Scope
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
- DECISION-MAKING SUMMARY
- INTRODUCTION
3.1. Overview of Biofilms Treatment
3.2. Key Historical Events
3.3. Structure
3.4. Biochemical Interaction
3.5. Target Indications
3.6. Advantages of Biofilms Treatment
3.7 Challenges associated with Biofilms Treatment
3.8. Future Perspectives.
- MARKET LANDSCAPE
4.1. Methodology
4.2 Biofilms Treatment: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters (Region-wise)
4.2.4. Analysis by Location of Headquarters (Country-wise)
4.2.5. Analysis by Year of Establishment, Company Size and Location of Headquarters (Region-wise)
4.2.6. Most Active Players
- COMPANY
5.1. Company Overview
5.1.2 Management Team
5.1.3. Product Portfolio
5.1.4. Recent Developments and Future Outlook
- PARTNERSHIPS AND COLLABORATIONS
6.1. Partnership Models
6.2. Biofilms Treatment: Partnerships and Collaborations
6.2.1. Analysis by Year of Partnership
6.2.2. Analysis by Type of Partnership
6.2.3. Analysis by Year and Type of Partnership
6.2.4. Analysis by Type of Partner
6.2.5. Analysis by Year of Partnership and Type of Partner
6.2.6. Analysis by Type of Partnership and Type of Partner
6.2.7. Analysis by Type of Partner and Parent Company Size
- ACADEMIC GRANTS ANALYSIS
7.1. Methodology and Key Parameters
7.2. Biofilms Treatment: Academic Grants Analysis
7.2.1. Analysis by Year of Grant Award
7.2.2. Analysis by Amount Awarded
7.2.3. Analysis by Funding Institute Center
7.2.4. Analysis by Support Period
7.2.5. Analysis by Funding Institute Center and Support Period
7.2.6. Analysis by Type of Grant Application
7.2.7. Analysis by Purpose of Grant
- PUBLICATION ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.2. Biofilms Treatment: Publication Analysis
8.2.1. Analysis by Year of Publication
8.2.2. Analysis by Type of Publication
8.2.3. Analysis by Type of Conjugate
8.2.4. Analysis by Target Indication
8.2.5. Analysis by Copyright Holder
8.2.6. Word Cloud: Emerging Focus Area
8.2.7. Most Active Publishers: Analysis by Number of Publications
- SUCCESS PROTOCOL ANALYSIS
9.1. Methodology and Key Parameters
9.2. Key Assumptions and Scoring Criteria
9.3. Success Protocol Analysis
9.4. Assessment of Approved Biofilms Treatment
- Appendix 1: Tabulated Data
- Appendix 2: List of Companies
- Smith+Nephew (U.K.)
- MiMedx (U.S.)
- ConvaTec Group plc (U.K.)
- Coloplast Group (Denmark)
- Mölnlycke Healthcare AB (Sweden)
- Organogenesis Inc. (U.S.)
- Integra LifeSciences (U.S.)
- Braun Melsungen AG (Germany)
- PAUL HARTMANN AG (Germany)
- Medline Industries Inc. (U.K.)
- Acelity (U.S.)
- Misonix (U.S.)
- Zimmer Biomet (U.S.)
- Kerecis (Iceland)
- Welcare Industries S.p.A (Italy)
